Green Cross Lab Cell Corporation Total Assets
Green Cross Lab Cell Corporation total assets. Based on the latest financial reports, Green Cross Lab Cell Corporation (144510) holds total assets worth ₩335.22 Billion KRW (≈ $227.17 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 144510 market cap for the company's overall valuation and market capitalisation.
Total Assets of Green Cross Lab Cell Corporation (2015–2025)
Total assets of Green Cross Lab Cell Corporation from 2015 to 2025. This chart illustrates how Green Cross Lab Cell Corporation's total assets have evolved over time, based on quarterly financial data. See 144510 live share price for real-time trading data and today's change.
Green Cross Lab Cell Corporation - Asset Composition Analysis
Green Cross Lab Cell Corporation Total Assets Breakdown (December 2025)
Green Cross Lab Cell Corporation total assets breakdown as of December 2025. Green Cross Lab Cell Corporation's total assets of ₩335.22 Billion consist of 11.9% current assets and 88.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0.5% |
| Accounts Receivable | ₩18.50 Billion | 6.1% |
| Inventory | ₩6.92 Billion | 2.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩20.21 Billion | 6.7% |
| Goodwill | ₩112.59 Billion | 37.1% |
Asset Composition Trend (2015–2025)
This chart illustrates how Green Cross Lab Cell Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 144510 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Green Cross Lab Cell Corporation's current assets represent 11.9% of total assets in 2025, a decrease from 46.2% in 2015.
- Cash Position: Cash and equivalents constituted 0.5% of total assets in 2025, up from 0.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 43.0% of total assets, an increase from 14.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 37.1% of total assets.
Green Cross Lab Cell Corporation Competitors by Total Assets
Key competitors of Green Cross Lab Cell Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
|
India | Rs15.07 Billion |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €18.96 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
Green Cross Lab Cell Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.52 | 0.59 | 1.98 |
| Quick Ratio | 0.44 | 0.50 | 1.97 |
| Cash Ratio | 0.00 | 0.00 | 0.99 |
| Working Capital | ₩-52.91 Billion | ₩-39.96 Billion | ₩29.03 Billion |
Green Cross Lab Cell Corporation - Advanced Valuation Insights
This section examines the relationship between Green Cross Lab Cell Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.17 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -47.5% |
| Total Assets | ₩303.69 Billion |
| Market Capitalization | $100.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values Green Cross Lab Cell Corporation's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Green Cross Lab Cell Corporation's assets decreased by 47.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Green Cross Lab Cell Corporation (2015–2025)
The table below shows the annual total assets of Green Cross Lab Cell Corporation from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩303.69 Billion ≈ $205.81 Million |
-47.49% |
| 2024-12-31 | ₩578.35 Billion ≈ $391.94 Million |
-13.05% |
| 2023-12-31 | ₩665.17 Billion ≈ $450.78 Million |
-1.68% |
| 2022-12-31 | ₩676.53 Billion ≈ $458.48 Million |
+4.80% |
| 2021-12-31 | ₩645.57 Billion ≈ $437.50 Million |
+745.41% |
| 2020-12-31 | ₩76.36 Billion ≈ $51.75 Million |
+12.19% |
| 2019-12-31 | ₩68.06 Billion ≈ $46.13 Million |
+18.85% |
| 2018-12-31 | ₩57.27 Billion ≈ $38.81 Million |
+3.45% |
| 2017-12-31 | ₩55.36 Billion ≈ $37.51 Million |
+1.54% |
| 2016-12-31 | ₩54.51 Billion ≈ $36.94 Million |
+223.28% |
| 2015-12-31 | ₩16.86 Billion ≈ $11.43 Million |
-- |
About Green Cross Lab Cell Corporation
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in Nove… Read more